HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehta, B. M. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Mehta, B. M. Articles by Larson, S. M.

In Vivo Uptake of Carbon-14-Colchicine for Identification of Tumor Multidrug Resistance

Nuclear Medicine Research Laboratory and Laboratory of Cellular and Biochemical Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence or reprints contact: Bipin M. Mehta, PhD, Nuclear Medicine Research Laboratory, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

ABSTRACT

A major limitation in the treatment of cancer with natural product chemotherapeutic agents is the development of multidrug resistance (MDR). Multidrug resistance is attributed to enhanced expression of the multidrug resistance gene MDR1. Colchicine (CHC) is known to be one of the MDR drugs. We have previously demonstrated that it is possible to distinguish multidrug-resistant tumors from multidrug-sensitive tumors in vivo on the basis of tritium (³H) uptake following injection of ³H-CHC. Methods: The present studies were carried out in xenografted animals using ¹⁴C-CHC which may be more indicative of ¹¹C-labeled CHC distribution with regard to circulating metabolites, since metabolic processes following injection of (ring C, methoxy-¹¹C)-CHC may produce significant amounts of circulating 1-carbon fragments (i.e., methanol and/or formaldehyde). Experiments were carried out at a dose of 2 mg/kg. Results: Activity concentration per injected dose was approximately twice as great in sensitive as in resistant tumors (p < 0.05) at 60 min following intravenous injection of ¹⁴C-CHC. About 75% of total activity was CHC in the sensitive tumors. The findings are further confirmed by the quantitative autoradiographic evaluation of resistant and sensitive tumors. Conclusions: These studies confirm our previous observations that it is possible to noninvasively distinguish multidrug-resistant tumors from sensitive tumors in vivo based on uptake of an injected MDR drug using a ¹⁴C-labeled CHC at the same position and of comparable specific activity to a ¹¹C-CHC tracer used for PET imaging.

Key Words: multidrug resistance • colchicine • P-glycoprotein

This article has been cited by other articles:

				N. H. Hendrikse, E. G. E. de Vries, L. Eriks-Fluks, W. T. A. van der Graaf, G. A. P. Hospers, A. T. M. Willemsen, W. Vaalburg, and E. J. F. Franssen A New in Vivo Method to Study P-Glycoprotein Transport in Tumors and the Blood-Brain Barrier Cancer Res., May 1, 1999; 59(10): 2411 - 2416. [Abstract] [Full Text] [PDF]